PCA
BCRX icon

Pallas Capital Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pallas Capital Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$101K Buy
+10,059
New +$91K ﹤0.01% 950
2025
Q3 		– Sell
-14,079
Closed -$126K – 882
2025
Q2 		$126K Sell
14,079
-5,718
-29% -$53.3K ﹤0.01% 786
2025
Q1 		$148K Buy
+19,797
New +$160K 0.01% 697

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Pallas Capital Advisors's BCRX Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 10,059 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #950 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in BCRX as recently as Q2 2025.

Pallas Capital Advisors first reported a position in BCRX in Q1 2025 and has held it in 3 quarters since. The position peaked at $148K in Q1 2025. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Pallas Capital Advisors held 10,059 shares of BioCryst Pharmaceuticals worth $101K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Pallas Capital Advisors position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #950 holding.
  • Pallas Capital Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Pallas Capital Advisors's BioCryst Pharmaceuticals position peaked at $148K in Q1 2025.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.